A Phase I Trial to Determine the Maximum Tolerated Dose and Patient-specific Dosimetry of Fractionated Intracavitary Radioimmunotherapy with Lu-177 Labeled 6A10 Fab-fragments in Patients with Glioblastoma After Standard Treatment

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LuCaFab injection-Helmholtz Zentrum Munchen/ITM Group (Primary)
Indications Glioblastoma
Focus Adverse reactions

Most Recent Events

30 Mar 2025 Planned End Date changed from 1 Jun 2025 to 1 Apr 2026.
30 Mar 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Apr 2026.
23 Apr 2024 According to an ITM Isotope Technologies Munich SE media release, company announce first patient dosed in phase I investigator-initiated glioblastoma trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight